Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A20 inhibits the release of inflammatory cytokines by suppressing the activation of the nuclear factor-kappa B pathway in osteoarthritic fibroblast-like synoviocytes.

Biochemical and biophysical research communications·2018

Same author

Dual specificity phosphatase 1 has a protective role in osteoarthritis fibroblast‑like synoviocytes via inhibition of the MAPK signaling pathway.

Molecular medicine reports·2017

Same author

Retraction Note To: VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.

Cell biochemistry and biophysics·2017

Same author

Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model.

Oncology letters·2017

Same author

VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.

Cell biochemistry and biophysics·2016

Same author

VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway.

International journal of clinical and experimental medicine·2015

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Association between TGFBR1*6A and osteosarcoma: a Chinese case-control study.

Yun-Sheng Hu¹, Yong Pan, Wen-Hai Li

¹Center of Orthopaedic Surgery, Orthopaedic Oncology Institute of PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. huys11@sina.com

|May 1, 2010

Summary

The TGFBR1*6A variant increases osteosarcoma risk and metastasis. This common polymorphism in transforming growth factor beta receptor 1 (TGFBR1) is linked to higher susceptibility in patients.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Area of Science:

Genetics
Oncology
Molecular Biology

Background:

The TGFBR1*6A variant is a common hypomorphic variant of transforming growth factor beta receptor 1 (TGFBR1).
While TGFBR1*6A is linked to increased cancer risk, its association with osteosarcoma is not well understood.
This study investigates the frequency of TGFBR1*6A variants in osteosarcoma cases and controls.

Purpose of the Study:

To determine the frequency of the TGFBR1*6A variant in osteosarcoma patients and healthy controls.
To assess the association between the TGFBR1*6A polymorphism and osteosarcoma susceptibility.
To explore the relationship between TGFBR1*6A and clinicopathological features, including metastasis.

Main Methods:

A case-control study involving 168 osteosarcoma patients and 168 matched controls.
DNA was extracted from blood samples, and the TGFBR1*6A variant was identified using PCR amplification and DNA sequencing.
Unconditional logistic regression was employed to calculate odds ratios (OR) and 95% confidence intervals (95% CI), adjusting for age and gender.

Main Results:

The TGFBR1*6A variant was significantly more frequent in osteosarcoma cases (50.4% heterozygous, 6.0% homozygous) compared to controls (18.5% heterozygous, 1.3% homozygous).
The additive model showed significantly increased odds ratios for both heterozygosity (OR=2.9) and homozygosity (OR=4.6) of the TGFBR1*6A allele.
TGFBR1*6A genotypes were not associated with age, gender, or tumor location but were significantly associated with reduced metastasis.

Conclusions:

The TGFBR1*6A polymorphism is associated with increased susceptibility to osteosarcoma.
This variant also appears to be linked to the spread of metastasis in osteosarcoma patients.
TGFBR1*6A represents a significant genetic factor influencing osteosarcoma development and progression.